Diabetic Neuropathy Market: Comprehensive Study Explores Huge Growth in Future: Pfizer, Janssen Pharma, Eli Lilly and Company, Teva Pharma, Cephalon
An estimated 50% of the diabetic population suffers from diabetic neuropathy across the globe. Further, as per the Center For Disease Control estimates, 6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the United States. Increase in prevalence of diabetes due to the sedentary lifestyle, the rise in obese population due to improper diet, and growth in awareness regarding diagnosis & treatment of diabetes. These factors are propelling the growth of the market. Diabetic neuropathy is a nerve-damaging...
View full press release